Bioptimus Launches H-optimus-1 on AWS Marketplace, Bringing Powerful AI to Pathology Workflows Worldwide

Bioptimus, the French AI startup building the world’s first multi-modal foundation model for biology, today announced that H-optimus-1, its state-of-the-art AI model for histopathology, is now available on Amazon Web Services (AWS) Marketplace. This launch gives healthcare and life sciences organizations immediate access to deploy Bioptimus’s cutting-edge pathology model in their own secure cloud environments.

Released in March 2025, H-optimus-1 is trained on millions of whole-slide pathology images and delivers best-in-class performance across essential diagnostic and research tasks—such as cancer subtype classification, tumor grading, biomarker detection, and quality control of digital slides. With availability on AWS Marketplace, commercial and academic partners can now easily procure and integrate this model into their AWS-based workflows, accelerating time to insight and improving efficiency in pathology and biomedical R&D.

AWS Marketplace is a curated digital catalog that makes it easy for organizations to discover, test, buy, and deploy software that runs on AWS. Customers benefit from streamlined procurement, simplified billing, and the ability to launch directly into their cloud infrastructure with confidence in security and scalability.

Although H-optimus-1 marks a major step forward in digital pathology, it is just the beginning of Bioptimus’s broader roadmap. The company is currently developing a multi-modal foundation model for biology capable of learning from genomics, molecular data, medical imaging, and clinical records—an ambitious platform designed to drive breakthroughs across a wide range of biomedical and industrial applications. The next model in this phased approach, M-optimus, is slated for release later this year.

Jean-Philippe Vert, CEO and co-founder of Bioptimus, said:

“This is more than a model—it’s a step toward a deeper, AI-driven understanding of life itself. By partnering with AWS, we’re making that vision real today, starting with pathology and moving toward a truly multi-modal future.”

Bioptimus will continue working with AWS to make H-optimus-1 accessible in more ways to customers.